Adaptive Radiotherapy: Advanced Imaging for Personalised Treatment

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 15 February 2026 | Viewed by 698

Special Issue Editors


E-Mail Website
Guest Editor
Department of Radiation Oncology, Austin Health, Melbourne, VIC 3004, Australia
Interests: radiation oncology; MRI; adaptive radiotherapy; precision oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
GenesisCare, St Vincent’s Hospital, Sydney, NSW 2010, Australia
Interests: medical physics; radiation oncology; MRI; dosimetry; adaptive radiotherapy

Special Issue Information

Dear Colleagues,

Adaptive radiotherapy has been growing in prominence in recent years. It can take the form of CT-based or MR-based adaptation. . Adaptations aim to maintain dosimetry accuracy, to improve coverage for tumoural changes, and/or to reduce the dose to surrounding normal tissues.

This Special Issue aims to provide up-to-date articles on the use of adaptive radiotherapy in radiation oncology.

Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Optimization of CT and/or MR images for visualizing cancer, contouring and assessing treatment response;
  • Image registration;
  • Dose cumulation strategies;
  • Treatment planning;
  • CT-guided and/or MR-guided adaptive radiotherapy;
  • Novel adaptation techniques.

Dr. Sweet Ping Ng
Dr. Michael G. Jameson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adaptive radiotherapy
  • advanced imaging
  • personalized radiotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 1326 KB  
Review
MR-Guided Radiotherapy in Oesophageal Cancer: From Principles to Practice—A Narrative Review
by Su Chen Fong, Eddie Lau, David S. Liu, Niall C. Tebbutt, Richard Khor, Trevor Leong, David Williams, Sergio Uribe and Sweet Ping Ng
Curr. Oncol. 2026, 33(1), 34; https://doi.org/10.3390/curroncol33010034 - 8 Jan 2026
Viewed by 226
Abstract
Oesophageal cancer remains a significant global health burden with poor survival outcomes despite multimodal treatment. Recent advances in magnetic resonance imaging (MRI) have opened opportunities to improve radiotherapy delivery. This review examines the role of MRI and MR-guided radiotherapy (MRgRT) in oesophageal cancer, [...] Read more.
Oesophageal cancer remains a significant global health burden with poor survival outcomes despite multimodal treatment. Recent advances in magnetic resonance imaging (MRI) have opened opportunities to improve radiotherapy delivery. This review examines the role of MRI and MR-guided radiotherapy (MRgRT) in oesophageal cancer, focusing on applications in staging, treatment planning, and response assessment, with particular emphasis on magnetic resonance linear accelerator (MR-Linac)-based delivery. Compared to computed tomography (CT), MRI offers superior soft-tissue contrast, enabling more accurate tumour delineation and the potential for reduced treatment margins. Real-time MR imaging during treatment can facilitate motion management, while daily adaptive planning can accommodate anatomical changes throughout the treatment course. Functional MRI sequences, including diffusion-weighted and dynamic contrast-enhanced imaging, offer quantitative data for treatment response monitoring. Early clinical and dosimetric studies demonstrate that MRgRT can significantly reduce radiation dose to critical organs while maintaining target coverage. However, clinical evidence for MRgRT in oesophageal cancer is limited to small early-phase studies, with no phase II/III trials demonstrating improvements in survival, toxicity, or patient-reported outcomes. Long-term clinical benefits and cost-effectiveness remain unproven, highlighting the need for prospective outcome-focused studies to define the role for MRgRT within multimodality treatment pathways. Full article
(This article belongs to the Special Issue Adaptive Radiotherapy: Advanced Imaging for Personalised Treatment)
Show Figures

Figure 1

Back to TopTop